Seegnal (TSXV: SEGN) has announced that it has successfully initiated its first pilot program in the U.S., following the letter of intent, announced on May 19, 2026.
The company, dedicated to reducing medication-related harm where care begins, reports that the pilot program is being conducted with a U.S.-based long-term care provider and is expected to run between eight and 12 weeks from the receipt of data, followed by a potential extended evaluation period.
In a statement, Elad Bibi-Aviv, CEO of Seegnal, commented, “Initiating this pilot is an important step in executing on our U.S. commercial strategy. Long-term care is a setting where medication complexity, polypharmacy, and the need for individualized prescribing decisions converge. These are areas where our platform was designed to add value. We look forward to working with our pilot partner and to reporting on progress in due course.”
